Logo
x

Search

Subscribe Now

egfr

Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer

Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer

  • October 18, 2021
AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's Priority Review for the Adjuvant Treatment of Patients with Early-Stage...

  • October 20, 2020
The US FDA Approves Guardant360 CDx as the First Liquid Biopsy NGS Assay to Identify EGFR Mutations in Non-Small Cell Lung Cancer

The US FDA Approves Guardant360 CDx as the First Liquid Biopsy NGS Assay to Identify EGFR Mutations in Non-Small Cell Lung Cancer

  • August 10, 2020
AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lu...

  • August 9, 2019
Burning Rock and Dizal Reports China

    Burning Rock and Dizal Reports China's NMPA Approval of Co-Developed Companion Diagnostic (CDx) for Lung Cancer

    • October 11, 2024
    BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

      BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

      • October 4, 2024
      AstraZeneca’s Tagrisso Receives the US FDA’s Approval for Treating Unresectable, Stage III EGFR-Mutated Lung Cancer

        AstraZeneca’s Tagrisso Receives the US FDA’s Approval for Treating Unresectable, Stage III EGFR-Mutated Lung Cancer

        • September 26, 2024
        Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Plus Standard of Care to Treat EGFR-Mutated NSCLC

          Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Plus Standard of Care to Treat EGFR-Mutated NSCLC

          • September 20, 2024
          Merck and Daiichi Sankyo Report the P-III (HERTHENA-Lung02) Study Data of Patritumab Deruxtecan to Treat Non-Small Cell Lung Cancer

            Merck and Daiichi Sankyo Report the P-III (HERTHENA-Lung02) Study Data of Patritumab Deruxtecan to Treat Non-Small Cell Lung Cance...

            • September 17, 2024
            Insights+: The US FDA New Drug Approvals in August 2024

              Insights+: The US FDA New Drug Approvals in August 2024

              • September 10, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.